RXi Pharmaceuticals

NASDAQ: RXII - Developing the next generation of immuno-oncology therapeutics.

[RXi Pharmaceuticals @RXiPharma]

$RXII Pharmaceuticals Corporation completes name change to $PHIO Pharmaceuticals Corp. Check out our new website at https://t.co/lJ0bnkq5RM and follow us @phio_pharma for updates. https://t.co/pRLakcp4gJ

[RXi Pharmaceuticals @RXiPharma]

$RXII Reports Q3 2018 #Financial Results & Corporate Highlights:
•Gerrit Dispersyn appointed President & COO
•Planned corporate name change from RXi to Phio
•Extended cash runway
•Reduced net loss
•Announced new #nkcell data using #sdrxrna
https://t.co/cx1Q3BwucG

[RXi Pharmaceuticals @RXiPharma]

"Pharm Exec's 2019 Pipeline Report" published by @PharmExec includes $RXII development of immuno-oncology therapeutics using its self-delivering RNAi platform: https://t.co/V1bst9MS8l

[RXi Pharmaceuticals @RXiPharma]

$RXII to present poster at #SITC2018 on 11/10/2018 from 12:20pm – 1:50pm ET & 7:00 – 8:00pm ET. Poster will highlight the potential of #sdrxrna to improve #nkcell potency in #adoptivecelltherapy. https://t.co/CeB5qVYVLB

[RXi Pharmaceuticals @RXiPharma]

$RXII to webcast third quarter 2018 #Financial results and provide a business update: 11/14/2018 at 4:30pm ET https://t.co/7iZMbScKC9

[RXi Pharmaceuticals @RXiPharma]

Cartoons offer a peek into cancer immunotherapy — and scientists’ minds https://t.co/GMsaTlytzu via @statnews

[RXi Pharmaceuticals @RXiPharma]

RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering | RXi Pharmaceuticals https://t.co/Ih93ABW11e

[RXi Pharmaceuticals @RXiPharma]

$RXII Announces Pricing of $15M Upsized Underwritten Public Offering https://t.co/NfxNF47uRe

[RXi Pharmaceuticals @RXiPharma]

$RXII presentation today at #BostonDOT18. "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity" - https://t.co/1KXHYnjXvP

#cancer #ImmunoOncology #RNAi #adoptivecelltherapy #Cbl-b

[RXi Pharmaceuticals @RXiPharma]

Listen in to RXi's recent webcast presentation to learn about our strategy to tackle different #immune escape mechanisms to treat solid #tumors and view data from our collaborations with #CCIT, #Medigene and #GustaveRoussy #ImmunoOncology https://t.co/mBFGqv8UZO

[RXi Pharmaceuticals @RXiPharma]

$RXII: Cancer Care’s Next Chapter Could Depend on RNA Interference. "The potential of sd-rxRNA...to address the enduring challenges of undruggable targets...could offer oncologists a new way to address the needs of their patients." #ImmunoOncology #RNAi

https://t.co/OrLPUN1n9U

[RXi Pharmaceuticals @RXiPharma]

$RXII to present at Rodman&Renshaw Global #Investment Conf. 9/5/18 at 3:25 p.m. ET. Update on #ImmunoOncology programs that aim to fill unmet need of other therapeutic approaches and strategy to tackle different #immune escape mechanisms to treat #cancer https://t.co/k9VhPTtJ4R

[RXi Pharmaceuticals @RXiPharma]

$RXII & #Karolinska Institutet Enter Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of #TCells and #NKCells for the Advancement of #ImmunoOncology Therapeutics for #SolidTumors
#cancer #rnai
https://t.co/rYZrDud0C7

[RXi Pharmaceuticals @RXiPharma]

$RXII Reports Q2 2018 #Financial Results & Corporate Highlights:
•Extended cash runway
•Announced positive #dermatology and #ophthalmology results
•Entered collaboration w/ #Iovance Biotherapeutics
• Strengthened IP estate for sd-rxRNA platform
https://t.co/t65rXD52Bj

[RXi Pharmaceuticals @RXiPharma]

$RXII to webcast second quarter 2018 #financial results and provide a business update: 08/14/2018 at 4:30 pm ET. https://t.co/egIwGxPc34

[RXi Pharmaceuticals @RXiPharma]

$RXII granted patents for sd-rxRNA technology strengthening #IP estate in Europe and Japan. Further provides for multiple #commercial and #development opportunities. #businessdevelopment https://t.co/XuhkiylCsv

[RXi Pharmaceuticals @RXiPharma]

$RXII Announces Postive #Results from Phase 1/2 trial with #RXI-109 for #Retinal Scarring #investors #ophthalmology #wetAMD https://t.co/2F9oEt4SFD

[RXi Pharmaceuticals @RXiPharma]

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of #sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury- Collaborator #RXII to receive a portion of the funding https://t.co/tM5prDfqy1

[RXi Pharmaceuticals @RXiPharma]

Cancer Immunotherapy and RNA Interference https://t.co/6T55Bqd9pE via @genbio

[RXi Pharmaceuticals @RXiPharma]

RXi leveraging European partnerships to focus on new cancer treatments https://t.co/1lwhTCm3w5